Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Trading for cash

<< Previous

Bullboard Posts

Next >>

Post by Amigo11on Aug 19, 2021 7:02am

174 Views

Post# 33728981

Trading for cash

We ve lost any momentum,and are back trading for cash value per share.This is what bottom looks and feels like.-lots of big offerings of shares,negative sentiment if not despair,and complete loss of confidence in the company/management.Everyone remember what this feels like.It ll make the journey more enjoyable later.Imagine a successful Canadian leader in pain management after all this !

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth